Bofanglutide clinical trials
Also written GZR18.
How each study uses bofanglutide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the bofanglutide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
25 studies that test it; most in 2025 (9)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 3 |
| 2024 | 3 |
| 2025 | 9 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 25 · Other 0
Gan & Lee Pharmaceuticals. (13) · Gan and Lee Pharmaceuticals, USA (10) · Carnot Laboratories (2)
Often tested with
Tested in the same studies.
GZR102 (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3, 3 in phase 3
Studies that test bofanglutide, phase 3 first.
- Jun 2027Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight SubjectsPhase 3 · Gan & Lee Pharmaceuticals.
- Oct 2027BALANCE-DM2 Study of Bofanglutide in Adults With Type 2 DiabetesPhase 3 · Carnot Laboratories
- Nov 2027Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Not Treated With Positive Airway Pressure (PAP) TherapyPhase 3 · Gan & Lee Pharmaceuticals.
Studies
Open first, then newest update. How each study uses bofanglutide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 25
- Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Not Treated With Positive Airway Pressure (PAP) TherapyRecruitingPhase 3Gan & Lee Pharmaceuticals.NCT07493057Written as GZR18 injection
- Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Receiving Positive Airway Pressure (PAP) TherapyRecruitingPhase 3Gan & Lee Pharmaceuticals.NCT07501832Written as GZR18 injection
- BALANCE-DM2 Study of Bofanglutide in Adults With Type 2 DiabetesNot yet recruitingPhase 3Carnot LaboratoriesNCT07628985Written as Bofanglutide
- BALANCE-OBS: Bofanglutide (GZR18) Versus Semaglutide in Latin American Adults With Overweight or ObesityNot yet recruitingPhase 3Carnot LaboratoriesNCT07622810Written as Bofanglutida
- Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight SubjectsRecruitingPhase 3Gan & Lee Pharmaceuticals.NCT07150975Written as GZR18
- A Phase I Clinical Study to Evaluate the Effect of GZR18 Injection on the Pharmacokinetics of Oral Metformin Hydrochloride Tablets in Overweight/Obese SubjectsNot yet recruitingPhase 1Gan and Lee Pharmaceuticals, USANCT06670209Written as GZR18 and metformin
- A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Obese/Overweight SubjectsCompletedPhase 3Gan & Lee Pharmaceuticals.NCT06728124Written as GZR18
- Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Liver Insufficiency and Normal Liver FunctionCompletedPhase 1Gan & Lee Pharmaceuticals.NCT07144098Written as GZR18 injection
- A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes MellitusCompletedPhase 3Gan & Lee Pharmaceuticals.NCT06778967Written as GZR18
- A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Subjects With Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Diet and ExerciseCompletedPhase 3Gan & Lee Pharmaceuticals.NCT06777238Written as GZR18
- Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Renal Impairment and Normal Renal FunctionCompletedPhase 1Gan & Lee Pharmaceuticals.NCT07141030Written as GZR18 injection
- Study on Gastric Emptying Effect and Drug-Drug Interactions of GZR18 InjectionCompletedPhase 1Gan & Lee Pharmaceuticals.NCT07128888Written as GZR18 injection,digoxin tablets, rosuvastatin calcium tablets and warfarin sodium tablets
- Bioequivalence Study of GZR18 Injection Before and After CMC ChangeCompletedPhase 1Gan & Lee Pharmaceuticals.NCT07355738Written as GZR18 injection A
- Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight LossCompletedPhase 3Gan & Lee Pharmaceuticals.NCT07292441Written as GZR18 injection
- Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight ParticipantsCompletedPhase 2Gan and Lee Pharmaceuticals, USANCT06737042Written as GZR18
- A Study to Compare the Efficacy and Safety of GZR102 Injection and GZR18 Injection in Type 2 Diabetes MellitusActive, not recruitingPhase 2Gan & Lee Pharmaceuticals.NCT07055386Written as GZR18
- The Study of [14C] GZR18CompletedPhase 1Gan & Lee Pharmaceuticals.NCT07119450Written as GZR18 injection、[14C]GZR18 injection
- A Study of GZR18 Injection in Obese/Overweight PatientsCompletedPhase 2Gan and Lee Pharmaceuticals, USANCT06256562Written as GZR18
- A Study of GZR18 Tablet in Chinese Healthy SubjectsActive, not recruitingPhase 1Gan and Lee Pharmaceuticals, USANCT06554054Written as GZR18
- A Phase I Study of GZR18 Injection in Healthy SubjectsCompletedPhase 1Gan and Lee Pharmaceuticals, USANCT06548997Written as GZR18
See all 25 studies that test bofanglutide →
As the comparator · 1 — what is tested is compared with bofanglutide
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting2
- Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Not Treated With Positive Airway Pressure (PAP) TherapyNov 12, 2026NCT07493057
- Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Receiving Positive Airway Pressure (PAP) TherapyNov 12, 2026NCT07501832
Codes
What other systems call bofanglutide · ClinicalTrials.gg INT018450
- UNII (FDA) X9RLV48FDHBOFANGLUTIDEOne source FDA
- NCI Thesaurus C206886BofanglutideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | X9RLV48FDH | BOFANGLUTIDE | One source FDA |
| NCI Thesaurus | C206886 | Bofanglutide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.